21 Recruiting Studies Using Encorafenib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Encorafenib
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
📍 Providence Portland Medical Center — Portland, Oregon
BRAF NP_004324.2:p.V600M
View Study & Checklist ➔A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
📍 Mayo Clinic Building - Phoenix — Phoenix, Arizona
Metastatic Colorectal Cancer
View Study & Checklist ➔Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
📍 Centro Oncologico Korben — CABA, Buenos Aires
Melanoma
View Study & Checklist ➔A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
📍 Adventist Health System/Sunbelt, Inc. — Orlando, Florida
Melanoma
View Study & Checklist ➔Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
📍 CTCA at Western Regional Medical Center — Goodyear, Arizona
Metastatic Colon Adenocarcinoma
View Study & Checklist ➔Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Hairy Cell Leukemia
View Study & Checklist ➔Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
📍 Princess Margaret Cancer Centre — Toronto, Ontario
Solid Tumor
View Study & Checklist ➔Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
📍 M D Anderson Cancer Center — Houston, Texas
BRAF NP_004324.2:p.V600E
View Study & Checklist ➔A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
📍 Mayo Clinic Hospital — Phoenix, Arizona
Neoplasms
View Study & Checklist ➔Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Melanoma (Skin)
View Study & Checklist ➔Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
📍 Beebe South Coastal Health Campus — Millville, Delaware
Colon Adenocarcinoma
View Study & Checklist ➔Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Malignant Neoplasm in the Brain
View Study & Checklist ➔ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
📍 MD Anderson Cancer Center — Houston, Texas
Dynamic Tumor Resistance
View Study & Checklist ➔Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
📍 M D Anderson Cancer Center — Houston, Texas
Clinical Stage IV Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
📍 Moffitt Cancer Center — Tampa, Florida
Melanoma Stage III
View Study & Checklist ➔Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
📍 University of Iowa — Iowa City, Iowa
Metastatic Melanoma
View Study & Checklist ➔The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
📍 St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Solid Tumors
View Study & Checklist ➔Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
📍 University of Iowa — Iowa City, Iowa
Cutaneous Melanoma
View Study & Checklist ➔Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Colorectal Cancer
View Study & Checklist ➔Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
📍 Massachusetts General Hospital — Boston, Massachusetts
Metastatic Colon Cancer
View Study & Checklist ➔A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acral Lentiginous Melanoma
View Study & Checklist ➔